Recce Pharmaceuticals (ASX: $RCE) Business Update

Recce Pharmaceuticals Limited (ASX: $RCE, FSE:R9Q) has provided a business update, highlighting significant progress in its clinical trials and the securing of a USD $2.2 million grant for its R327G topical treatment for Burn Wound Infections from the US Department of Defence. The company has achieved promising results in its Phase I/II UTI/Urosepsis and DFI clinical trials, with plans to expand its Phase III registrational trial in Indonesia. Additionally, Recce is preparing to submit an Investigational New Drug (IND) Application with the US FDA in H2 2024 for trial initiation in H1 2025.

Executive Commentary

The progress made in our clinical trials is a testament to the potential of our synthetic anti-infectives. We are encouraged by the promising results in our Phase I/II UTI/Urosepsis and DFI trials, and the recognition from the US Department of Defence further validates the significance of our R327G topical treatment. We are dedicated to advancing medical research and delivering innovative solutions to address critical medical needs.

Summary

Recce Pharmaceuticals (ASX: $RCE) has made significant strides in its clinical trials, with promising results in the Phase I/II UTI/Urosepsis and DFI trials. The company is set to expand its Phase III registrational trial in Indonesia and is preparing to submit an Investigational New Drug (IND) Application with the US FDA. Additionally, the US Department of Defence has recommended a USD $2.2 million grant for Recce's R327G topical treatment for Burn Wound Infections. These developments underscore Recce's commitment to advancing innovative solutions in healthcare and its dedication to addressing global health challenges posed by antibiotic-resistant bacteria and emerging viral pathogens.